Aileron Therapeutics to Join Russell Microcap® Index

AUSTIN, Texas, July 1, 2024 -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced its inclusion in the Russell Microcap® Index. This inclusion will take effect at the open of US equity markets on Monday, July 1, 2024, following the 2024 Russell U.S. Indexes annual reconstitution.

The annual reconstitution of the Russell U.S. Indexes involves capturing the 4,000 largest U.S. stocks as of April 30th and ranking them by total market capitalization. Membership in the Russell Microcap® Index, which lasts for one year, ensures automatic inclusion in the relevant growth and value style indexes. FTSE Russell primarily determines membership based on objective market-capitalization rankings and style attributes.

Commenting on this development, Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron, stated, "Aileron's inclusion in the Russell Microcap Index is an exciting step in the Company's evolution, and representative of the clinical progress made for our lead asset, LTI-03, in patients with idiopathic pulmonary fibrosis." Windsor highlighted the importance of this increased exposure, referencing positive data from Cohort 1 of the Phase 1b trial, which demonstrated statistically significant biomarker movement in three out of eight markers. These results underscore the potential of LTI-03 to enhance lung function and alter the disease's progression.

Russell indexes are a critical tool for investment managers and institutional investors, serving as benchmarks for about $10.5 trillion in assets as of December 2023. These indexes are part of FTSE Russell, a leading global index provider.

Aileron Therapeutics is focused on developing innovative treatments for serious medical conditions. Its lead product candidate, LTI-03, is a novel synthetic peptide with dual mechanisms targeting alveolar epithelial cell survival and inhibiting profibrotic signaling. Currently, LTI-03 is under evaluation in a Phase 1b clinical trial for idiopathic pulmonary fibrosis. Another candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions and has received Orphan Drug Designation in both the US and EU, as well as Fast Track Designation in the US.

FTSE Russell is recognized globally for providing comprehensive benchmarking, analytics, and data solutions to investors. It offers a wide range of indexes that enable investors to measure and benchmark markets across various asset classes and strategies. For over three decades, institutional and retail investors have relied on FTSE Russell indexes for benchmarking investment performance and creating various financial products.

FTSE Russell prides itself on adhering to the highest industry standards in index design and governance, using a transparent rules-based methodology guided by independent committees of market participants. The organization fully supports the IOSCO Principles, with its Statement of Compliance receiving independent assurance. Through continuous client partnerships and addressing investor needs, FTSE Russell consistently enhances its index offerings.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!